Supplementary Figure S6 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Survival curves of patients stratified into two groups, cfDNA high shedders vs. cfDNA low shedders. CfDNA concentration was measured in the plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancer (TNBC). The median cfDNA concentration was used as the cutoff to stratify patients into high vs. low cfDNA-shedders. The survival endpoint was distant recurrence-free survival (DRFS). P values were calculated using the Wald test. Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy before surgery (T3).